# Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting
**AGENCY:**
National Institutes of Health, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on September 30th, 2025. The topic for this meeting will be “COVID-19 and New-Onset Diabetes.”
**DATES:**
The meeting will be held on September 30th, 2025, from 1:00 p.m. to 4:00 p.m. EDT.
**ADDRESSES:**
This meeting will be held via Teams online video conferencing platform. For details, and to register, please go to the virtual event's page: *https://events.gcc.teams.microsoft.com/event/df4251d8-f786-46a0-910d-50c602572311@14b77578-9773-42d5-8507-251ca2dc2b06.*
**FOR FURTHER INFORMATION CONTACT:**
For further information concerning this meeting, including a draft agenda, which will be posted when available, see the DMICC website, *https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022,* or contact Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, Bethesda, MD 20892, telephone: 301-435-1011; email: *[email protected].*
**SUPPLEMENTARY INFORMATION:**
In accordance with 42 U.S.C.285c-3, the DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The September 30, 2025 DMICC meeting will focus on “COVID-19 and New-Onset Diabetes.”
Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives or organizations should submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, oral comments will be allowed on a first-come, first-serve basis.
Members of the public who would like to receive email notification about future DMICC meetings can select to be added to the DMICC listserv when registering on the meeting's event page: *https://events.gcc.teams.microsoft.com/event/df4251d8-f786-46a0-910d-50c602572311@14b77578-9773-42d5-8507-251ca2dc2b06.*
Dated: July 31, 2025.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.